Aderis Report issue

For profit Phase 2
Founded: Boston MA United States (2002)
Status: Acquired by Schwarz Pharma (2005) → now UCB (2006)

Organization Overview

First Clinical Trial
2002
NCT00040001
First Marketed Drug
2005
methimazole (tapazole)
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aderis Pharmaceuticals | DISCOVERY THERAP

Active Ingredients

Marketed Drugs (4)

bethanechol (urecholine) (2007)

hydroxyzine (vistaril) (2008)

methimazole (tapazole) (2005)

sodium polystyrene sulfonate (kayexalate) (2011)

Drugs in Phase 2 Trials (1)

selodenoson (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1